JPRN-UMIN000022607已完成未知
Phase 2a study of peptide cocktail vaccine for patients with refractory pediatric central nervous system tumor - NCCV-CNS p2a
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 30years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Chemotherapy within 3 weeks prior to enrollment. 2) Radiation therapy within 2 weeks prior to enrollment. 3) Major surgery within 1 week prior to enrollment. 4) Allogeneic marrow transplant within 1 year to enrollment, or on-going GVHD. 5) Malignant pleural effusion, ascites or cardiac effusion required invasive treatment. 6) Synchronous or asynchronous (within 5 years) other cancer except carcinoma in situ or intramucosal carcinoma. 7) Active infection requires systemic therapy. 8) Active gastrointestinal bleeding required blood transfusion. 9) Any severe and/or uncontrolled medical conditions. severe interstitial pneumonia history. 10) History of severe interstitial pneumonia. 11) Severe psychiatric disorder. 12) Known serious drug allergy. 13) Woman during pregnancy, or impossible to discontine breast-feeding for 120 days after the final dose of study treatment. Patient or the partner without intent to use birth control. 14) Inadequate physical condition judged by investigator.
研究者
相似试验
已完成
不适用
Phase 1 study of peptide cocktail vaccine for patients with refractory pediatric sarcoma.refractory neurobrastoma, Ewing's sarcoma family of tumor, rhabdomyosarcoma and osteosarcomaJPRN-UMIN000010149ational Cancer Center Hospital East20
已完成
不适用
Phase 2a study of peptide cocktail vaccine and interferon-beta for patients with refractory pediatric central nervous system tumorrefractory pediatric central nervous system tumorsJPRN-UMIN000032774Osaka City General Hospital13
已完成
1 期
A phase I/II study for peptides cocktail vaccine in patients with progressive or recurrent malignant glioma.Malignant gliomaJPRN-UMIN000012774Department of Neurosurgery, Keio University School of Medicine20
已完成
1 期
PhaseI/II clinical study of peptide vaccine against advanced or recurrent gastric cancerAdvanced or recurrent gastric cancer refractory to standard therapeutic modalityJPRN-UMIN000004389Department of Gastroenterological Surgery,Graduate School of Medicine,Osaka University30
已完成
2 期
Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancerpancreatic cancerJPRN-UMIN000004641Department of Gastroenterology Juntendo University School of Medicine40